[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 6, 1982

Advances in Cardiovascular Pharmacology

JAMA. 1982;248(5):537-543. doi:10.1001/jama.1982.03330050021010

This is an exciting era in pharmacology, and cardiovascular pharmacology provides a good example of this excitement. Substantial advances have been made in our understanding of cardiovascular physiology and in the pathophysiology of the major diseases with which we are dealing: heart failure, hypertension, and coronary artery disease. The methods of diagnosis of cardiovascular diseases and of evaluating the efficacy of pharmacologic therapy have progressed also. Better patient care and innovative cardiovascular pharmacology have evolved because of these advances.

Not many years ago, if an investigator wanted to study an antiarrhythmic drug, he administered the drug to a hospitalized patient with an arrhythmia and did an ECG every half hour. Now we have coronary care units and electronic monitoring, including Holter tapes to monitor patients outside of the hospital during their daily activities. As a result, we can get better data more rapidly on the effect of new drugs. These